Skip to main content

Table 3 Meta-analysis for DFS/PFS

From: Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis

Comparison Studies HR (95%CI) PA value I2 PH value Model
Overall   7 2.28 (1.52, 3.41) < 0.001 81.3 < 0.001 R
Subgroup
Country Asian 6 2.63 (1.65, 4.17) < 0.001 77.7 0.000 R
Non-Asian 1 1.26 (0.99, 1.61) 0.062 R
Sample size < 200 3 1.74 (1.08, 2.80) 0.022 61.2 0.076 R
> 200 4 2.74 (1.37, 5.46) 0.004 88.6 0.000 R
Cutoff < 600 3 1.74 (1.08, 2.80) 0.022 61.2 0.076 R
> 600 4 2.74 (1.37, 5.46) 0.004 88.6 0.000 R
Cancer type
  Cervical cancer
Ovarian cancer 3 2.78 (1.04, 7.45) 0.042 90.2 0.000 R
Breast cancer 4 2.05 (1.30, 3.24) 0.002 72.3 0.013 R
TNBC 2 2.02 (1.05, 3.89) 0.035 81.4 0.021 R
Other BC type 2 2.64 (0.67, 10.39) 0.166 79.7 0.026 R
Follow-up
  < 48 m 4 2.42 (1.66, 3.52) 0.010 88.0 0.000 R
> 48 m 3 1.98 (1.16, 3.37) 0.005 70.8 0.033 R
  1. TNBC triple-negative breast cancer, PFS progression-free survival, DFS disease-free survival, m month, HR hazard ratio, CI confidence interval, R random-effects, PAP value for association, PHP value for heterogeneity